New weight loss product gets FDA approval for obese

 BOSTON — Scientists say a revolutionary new device, the size of a matchbox, could be the most effective weapon yet in the fight against obesity.

The vBloc, made by EnteroMedics Inc., provides new hope for the nearly one-third of obese adult Americans in the form of a tiny implant. The Food and Drug Administration approved pacemaker-like device is implanted into the abdomen. It works by sending electrical pulses through the nerve pathway between the brain and the stomach helping patients to feel full. Read More

Biosimilar drugs may curb health care costs

The first biosimilar drug approved for the U.S. market has put the spotlight on how such medications could help employers with their ongoing health care cost battle, while biologic-drug makers are fighting biosimilars in court.

Biosimilars are “closely similar” to biologics, according to the U.S. Food and Drug Administration. Biologics are costly specialty drugs used to treat diseases such as cancer, rheumatoid arthritis and diabetes. Read More

In Massachusetts, biotech firms account for a lot of value but few jobs

When we talk about biotech, we’re usually talking about dollars far more than we’re talking about jobs. But exactly how few jobs we’re talking about may surprise you. It may also help explain why the Massachusetts Life Science Center has struggled to bring about the kind of job growth once hoped for.  Read More

Safer sunscreen ingredients waiting approval from FDA

Greater awareness about what’s in everyday products and increased interest in healthy living means there has never been a better time to re-evaluate which sunscreens you use. The ingredients in some common chemical-based sunscreens are known to cause allergic reactions for some people and have been linked to reproductive and behavioral problems in animal studies. But luckily for the sun-safe and health conscious among us, there are lots of widely available all-natural, mineral-based sunscreen formulations that won’t cause any health problems on store shelves these days. Read More

New Research Leads to FDA Approval of First Drug to Treat Radiation Sickness Results Lead To Crucial Decision from Federal Agency








BALTIMOREMay 22, 2015 /PRNewswire-USNewswire/ — As a result of research performed by scientists at the University of Maryland School of Medicine (UM SOM), the U.S. Food and Drug Administration has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neupogen®, is the first ever approved for the treatment of acute radiation injury.

The research was done by Thomas J. MacVittie, PhD, professor, and Ann M. Farese, MA, MS, assistant professor, both in the University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology’s Division of Translational Radiation Sciences. The investigators did their research in a non-human clinical model of high-dose radiation.

“Our research shows that this drug works to increase survival by protecting blood cells,” said Dr. MacVittie, who is considered one of the nation’s leading experts on radiation research. “That is a significant advancement, because the drug can now be used as a safe and effective treatment for the blood cell effects of severe radiation poisoning.” Read More

The Rise and Fall of 3 Market Darling Healthcare Stocks

Within the upward trending Healthcare Sector lurks the siren call of the explosive potential of Biotech and Medical Equipment stocks. Investors flock to companies touting new drugs or devices to treat a variety of medical conditions.  Unfortunately, that explosive potential is a double-edged sword, as a dramatic rise in share price can later see an equally dramatic fall.

In the last three months three companies once favored by investors and analysts alike have seen share price declines ranging from 12% to 30%.  Here are the three stocks and the percentage drop of each:

•    Acrux Limited (ACR)    -30%

•    ResMed Inc. (RMD)    -15%

•    Sirtex Medical Limited    -12% 

Read More

Roche Receives FDA Approval For Its Cobas KRAS Mutation Test

Roche recently announced that the United States Food and Drug Administration (FDA) has approved its cobas KRAS Mutation Test to be used for diagnostic purposes. This real-time PCR test was developed to find KRAS mutations in tumor samples that are collected from patients with metastatic colorectal cancer (mCRC) and help clinicians to better determine a suitable therapeutic path.

“As more targeted treatment options for cancer patients become available, the importance of identifying the right molecular information to define their disease becomes critical. The cobas® KRAS Mutation Test gives clinicians actionable insights that enable them to make informed decisions about treatment for their patient. With this approval, Roche now offers the most comprehensive companion diagnostic FDA approved portfolio for oncology in the U.S., including tests for BRAF (melanoma), EGFR (lung cancer) and KRAS (mCRC) mutations,” explained Paul Brown, the Head of Roche Molecular Diagnostics. Read More

Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Cancer Drug Sales Expected To Soar By 2020

Global breast cancer branded drug sales may rise to $20 billion in 2020, compared to $13 billion reported in 2014, as per consensus data compiled by Bloomberg Intelligence, which only takes into account currently approved drugs. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) accounted for almost 70% of all breast cancer drug sales in 2014, while it is expected that Pfizer Inc. (NYSE:PFE) will be the key growth driver for 24% of sales in 2020 with its star breast cancer drug, Ibrance. New breast cancer drugs from Novartis AG (ADR) (NYSE:NVS) can add another $5 billion to global sales for the disease in 2020. Read More

1 Comment on "New weight loss product gets FDA approval for obese"

  1. Really high quality blog posts on this site, saved to fav.

Comments are closed.

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.